Zymeworks Inc. (ZYME) Q1 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. This is the conference operator. Welcome to DesignWorks' first quarter 2025 results conference call and webcast. As a reminder, all participants are in listen-only mode and the conference is being recorded. After the presentation, there will be an opportunity to ask questions. To ask a question, Thank you, Operator, and good afternoon, everyone. Thanks for joining our first quarter 2025 results conference call. Before we begin, I would like to remind you that we will be making a number of forward-listening statements during this call, including without limitation those forward-listening statements identified in our slides in the accompanying oral commentary. Forward-looking statements are based upon our current expectations and various assumptions and are subject to the usual risks and uncertainty associated with companies in our industry and at our stage of development. For a discussion of these risks and uncertainties, we refer you to our latest SEC filings as found on our website and as far as the SEC. In a moment, I'll be handing over to Leonie Paterson, our Executive Vice President and Chief and Business Officer who will be discussing recent business updates along with the financial results for our first quarter 2025. Following this, Dr. Paul Moore, our Chief Scientific Officer, will give an overview of our recent R&D developments, including highlights from our poster presentations at the American Association for Cancer Research. At the end of the call, Leonie, Paul, and Ken Galbraith, our Chair and CEO, will be available for Q&A, along with Dr. Sabine McCann, our recently appointed Senior Vice President of Clinical Development As a reminder, the audio and slides from this call will also be available on the TimeWorks website later toda...